Netols Asset Management’s Haemonetics HAE Stock Holding History

Netols Asset Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-100,939	Closed	-$3.26M	–	71
2015 Q3	$3.26M	Sell	100,939 -2,133	-2%	-$80.3K	0.74%	65
2015 Q2	$4.26M	Sell	103,072 -2,193	-2%	-$92.4K	0.84%	64
2015 Q1	$4.73M	Sell	105,265 -2,974	-3%	-$124K	0.92%	63
2014 Q4	$4.05M	Sell	108,239 -11,656	-10%	-$427K	0.78%	69
2014 Q3	$4.19M	Sell	119,895 -12,225	-9%	-$436K	0.8%	69
2014 Q2	$4.66M	Sell	132,120 -5,147	-4%	-$172K	0.75%	69
2014 Q1	$4.47M	Sell	137,267 -9,354	-6%	-$357K	0.72%	69
2013 Q4	$6.18M	Sell	146,621 -15,973	-10%	-$657K	0.94%	66
2013 Q3	$6.48M	Sell	162,594 -11,789	-7%	-$495K	0.97%	65
2013 Q2	$7.21M	Buy	+174,383	New	+$7.06M	1.12%	60

Other funds holding HAE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.3B AUM 29.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Netols Asset Management's HAE Position: Q4 2015 in Review

Netols Asset Management sold out of Haemonetics (HAE) in Q4 2015, closing a stake of 100,939 shares — an estimated $3.26M sold.

Netols Asset Management first reported a position in HAE in Q2 2013 and held it in 10 quarters. The position peaked at $7.21M in Q2 2013. 164 funds tracked by Wall St. Rank hold HAE as of Q4 2015.

Netols Asset Management reported no remaining Haemonetics position as of Q4 2015 after selling out during the quarter.
Netols Asset Management sold 100,939 Haemonetics shares in Q4 2015, an estimated $3.26M.
Netols Asset Management first reported a position in Haemonetics in Q2 2013 and held it in 10 quarters.
Netols Asset Management's Haemonetics position peaked at $7.21M in Q2 2013.
164 funds tracked by Wall St. Rank held Haemonetics as of Q4 2015.

Based on Netols Asset Management's 13F filing for Q4 2015, filed 11 Feb 2016.